Joe
09-19-2007, 08:40 PM
Breast cancer survivors who took a weekly dose of risedronate, sold as Actonel, lost significantly less bone than those who did not take the drug, according to a two-year study from the University of Pittsburgh School of Medicine presented this week at the 29th annual meeting of the American Society for Bone and Mineral Research.
More... (http://www.news-medical.net/?id=30080)
More... (http://www.news-medical.net/?id=30080)